Tags

Type your tag names separated by a space and hit enter

Cilostazol reduces dry eye symptoms and improve walking distance in patients with peripheral artery disease.
Clin Ter 2019 Sep-Oct; 170(5):e357-e363CT

Abstract

AIM OF THE STUDY

Cilostazol is a phosphodiesterase III inhibitor that has anti-inflammatory and immunomodulatory effects and can act with beneficial effect in Dry Eye Syndrome (DES). This clinical trial evaluates the effects of cilostazol on the tear film.

MATERIALS AND METHODS

Following the run-in period, subjects were randomly into two groups: 40 subjects treated with cilostazol and 40 no-treated subjects. The Walking Impairment Questionnaire (WIQ) has been administered to all patients.

RESULT

The data obtained from comparison of the two study groups A and B were, respectively, the following: Schirmer I: 10.2±0.2 Vs 13.8±0.4 (p< 0.001); Schirmer II: 3.8±0.1 Vs 4.6±0.2 (p<0.001); Break-up time (BUT) 4.2±0.3 Vs 6.5±0.2 (p<0.001) with disappearing of symptoms. The WIQ showed a significant difference in the walking distance (p<0.05) and calf pain severity (p<0.005) of treated patients. In comparison with the placebo group, treated patients showed an improvement (p<0.03) in calf pain severity.

CONCLUSION

The administration of cilostazol was effective, in reducing DES and improve walking distance questionnaire.

Authors+Show Affiliations

Department of Biomedical and Biotechnological Sciences, University of Catania.Research Centre "The Great Senescence", University of Catania.Department of Biomedical and Biotechnological Sciences, University of Catania.Research Centre "The Great Senescence", University of Catania.Department of Biomedical and Biotechnological Sciences, University of Catania.Research Centre "The Great Senescence", University of Catania.Department of Neurosciences - University of Catania.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31612193

Citation

Chisari, L M., et al. "Cilostazol Reduces Dry Eye Symptoms and Improve Walking Distance in Patients With Peripheral Artery Disease." La Clinica Terapeutica, vol. 170, no. 5, 2019, pp. e357-e363.
Chisari LM, Malaguarnera S, Grasso A, et al. Cilostazol reduces dry eye symptoms and improve walking distance in patients with peripheral artery disease. Clin Ter. 2019;170(5):e357-e363.
Chisari, L. M., Malaguarnera, S., Grasso, A., Malaguarnera, M., Chisari, G., Borzì, A. M., & Chisari, C. G. (2019). Cilostazol reduces dry eye symptoms and improve walking distance in patients with peripheral artery disease. La Clinica Terapeutica, 170(5), pp. e357-e363. doi:10.7417/CT.2019.2160.
Chisari LM, et al. Cilostazol Reduces Dry Eye Symptoms and Improve Walking Distance in Patients With Peripheral Artery Disease. Clin Ter. 2019;170(5):e357-e363. PubMed PMID: 31612193.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cilostazol reduces dry eye symptoms and improve walking distance in patients with peripheral artery disease. AU - Chisari,L M, AU - Malaguarnera,S, AU - Grasso,A, AU - Malaguarnera,M, AU - Chisari,G, AU - Borzì,A M, AU - Chisari,C G, PY - 2019/10/16/entrez KW - Cilostazol KW - Dry Eye Syndrome (DES) KW - Intermittent claudication KW - Peripheral artery disease KW - Therapy ocular surface SP - e357 EP - e363 JF - La Clinica terapeutica JO - Clin Ter VL - 170 IS - 5 N2 - AIM OF THE STUDY: Cilostazol is a phosphodiesterase III inhibitor that has anti-inflammatory and immunomodulatory effects and can act with beneficial effect in Dry Eye Syndrome (DES). This clinical trial evaluates the effects of cilostazol on the tear film. MATERIALS AND METHODS: Following the run-in period, subjects were randomly into two groups: 40 subjects treated with cilostazol and 40 no-treated subjects. The Walking Impairment Questionnaire (WIQ) has been administered to all patients. RESULT: The data obtained from comparison of the two study groups A and B were, respectively, the following: Schirmer I: 10.2±0.2 Vs 13.8±0.4 (p< 0.001); Schirmer II: 3.8±0.1 Vs 4.6±0.2 (p<0.001); Break-up time (BUT) 4.2±0.3 Vs 6.5±0.2 (p<0.001) with disappearing of symptoms. The WIQ showed a significant difference in the walking distance (p<0.05) and calf pain severity (p<0.005) of treated patients. In comparison with the placebo group, treated patients showed an improvement (p<0.03) in calf pain severity. CONCLUSION: The administration of cilostazol was effective, in reducing DES and improve walking distance questionnaire. SN - 1972-6007 UR - https://www.unboundmedicine.com/medline/citation/31612193/Cilostazol_reduces_dry_eye_symptoms_and_improve_walking_distance_in_patients_with_peripheral_artery_disease L2 - http://www.clinicaterapeutica.it/ojs/index.php/ClinicaTerapeutica/article/view/487/192 DB - PRIME DP - Unbound Medicine ER -